{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:19:58Z","timestamp":1782760798428,"version":"3.54.5"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:p>Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss of nuclear expression. Claudin-4, a tight junction protein, is expressed in most epithelial tumors but not in mesotheliomas. Methylthioadenosine phosphorylase (MTAP) is frequently co-deleted with cyclin-dependent kinase inhibitor 2a in mesotheliomas. These markers have proven useful in separating mesothelioma from its mimics, particularly when tumors are pleural based. In the peritoneum, BAP1 loss has been rarely reported in high-grade serous carcinomas, but overall, these markers have been minimally evaluated in ovarian serous borderline tumors and low-grade serous carcinomas. Thus, we assessed the utility of BAP1, claudin-4, and MTAP in the differential diagnosis of PM and low-grade serous neoplasms. Eighteen PM (16 epithelioid, 1 biphasic, and 1 sarcomatous), 24 low-grade serous carcinomas, and 25 serous borderline tumors were stained for BAP1, claudin-4, and MTAP. Loss of BAP1 nuclear expression was observed in 12 (67%) PM (11 epithelioid, 1 biphasic) but was retained in all serous tumors. Claudin-4 was positive in all serous tumors and negative in all PM. Complete loss of cytoplasmic MTAP was noted in 3 (17%) PMs and 1 (4%) serous borderline tumor, while all low-grade serous carcinomas showed retained expression. BAP1 loss reliably distinguishes PM from serous tumors, although it lacks sensitivity. Claudin-4 is a reliable marker to exclude PM. MTAP loss may occur in both PM and serous tumors, and thus is not useful in distinguishing these entities.<\/jats:p>","DOI":"10.1097\/pgp.0000000000000877","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:01:03Z","timestamp":1651766463000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["BAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma"],"prefix":"10.1097","volume":"42","author":[{"given":"Kyle M.","family":"Devins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Zukerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn C.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin Pun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"R1-20250802","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00000478-198104000-00004","article-title":"Papillary peritoneal tumors in women","volume":"5","author":"Foyle","year":"1981","journal-title":"Am J Surg Pathol"},{"key":"R2-20250802","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/00000478-198908000-00004","article-title":"Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma. A histochemical and immunohistochemical comparison","volume":"13","author":"Bollinger","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"R3-20250802","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R4-20250802","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"R5-20250802","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00428-007-0448-x","article-title":"Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions","volume":"451","author":"Facchetti","year":"2007","journal-title":"Virchows Arch"},{"key":"R6-20250802","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"R7-20250802","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING \u00aenger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"R8-20250802","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.humpath.2018.05.012","article-title":"The diagnostic role of BAP1 in serous effusions","volume":"79","author":"Davidson","year":"2018","journal-title":"Hum Pathol"},{"key":"R9-20250802","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R10-20250802","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/ajcp\/aqw161.034","article-title":"BAP1 preserved in BRCA-mutated serous carcinoma","volume":"146","author":"McGregor","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"R11-20250802","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici","year":"2016","journal-title":"Hum Pathol"},{"key":"R12-20250802","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DD3","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod Pathol"},{"key":"R13-20250802","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1097\/PAS.0000000000000935","article-title":"PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma","volume":"41","author":"Chapel","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R14-20250802","first-page":"1185","article-title":"Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation","volume":"22","author":"Choi","year":"2007","journal-title":"Histol Histopathol"},{"key":"R15-20250802","doi-asserted-by":"crossref","first-page":"151582","DOI":"10.1016\/j.anndiagpath.2020.151582","article-title":"Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression","volume":"48","author":"Nilforoushan","year":"2020","journal-title":"Ann of Diagn Pathol"},{"key":"R16-20250802","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250802","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00000478-199609000-00004","article-title":"Malignant mesotheliomas presenting as ovarian masses: a report of nine cases, including two primary ovarian mesotheliomas","volume":"20","author":"Clement","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"R18-20250802","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2559.1983.tb02242.x","article-title":"Papillary mesothelioma of ovary","volume":"7","author":"Addis","year":"1983","journal-title":"Histopathology"},{"key":"R19-20250802","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00004347-198909000-00001","article-title":"Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison","volume":"8","author":"Wick","year":"1989","journal-title":"Ing J Gynecol Pathol"},{"key":"R20-20250802","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/00000478-199510000-00003","article-title":"Localized and diffuse mesotheliomas of the genital tract and peritoneum in women: a clinicopathologic study of nineteen true mesothelial neoplasms, other than adenomatoid tumors, multicystic mesotheliomas, and localized fibrous tumors","volume":"19","author":"Goldblum","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R21-20250802","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00000478-199003000-00004","article-title":"Serous borderline tumors of the peritoneum","volume":"14","author":"Bell","year":"1990","journal-title":"Am J Surg Pathol"},{"key":"R22-20250802","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin Epidemiol"},{"key":"R23-20250802","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu","year":"2014","journal-title":"Pathology"},{"key":"R24-20250802","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/0046-8177(89)90006-3","article-title":"Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases","volume":"20","author":"Raju","year":"1989","journal-title":"Hum Pathol"},{"key":"R25-20250802","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000478-199904000-00004","article-title":"Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns","volume":"23","author":"Eichhorn","year":"1999","journal-title":"Am J Surg Pathol"},{"key":"R26-20250802","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion","volume":"40","author":"Ahn","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R27-20250802","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R28-20250802","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R29-20250802","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1200\/JCO.20.02190","article-title":"MEK inhibitors for the treatment of low-grade serous ovarian cancer: expanding therapeutic options for a rare ovarian cancer subtype","volume":"38","author":"Gershenson","year":"2020","journal-title":"J Clin Oncol"},{"key":"R30-20250802","first-page":"775","article-title":"Ovarian cystectomy for serous borderline tumors: a follow-up study of 35 cases","volume":"72","author":"Lim-Tan","year":"1988","journal-title":"Obstet Gynecol"},{"key":"R31-20250802","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/modpathol.3800471","article-title":"The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study","volume":"19","author":"Ordonez","year":"2006","journal-title":"Mod Pathol"},{"key":"R32-20250802","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/1097-0142(20001025)90:5<312::AID-CNCR8>3.0.CO;2-M","article-title":"Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations","volume":"90","author":"Wieczorek","year":"2000","journal-title":"Cancer"},{"key":"R33-20250802","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3800259","article-title":"Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma","volume":"18","author":"Chu","year":"2005","journal-title":"Mod Pathol"},{"key":"R34-20250802","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","article-title":"GATA 3\u2014a multispecific but potentially useful marker in surgical pathology\u2014a systematic analysis of 2500 epithelial and non-epithelial tumors","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R35-20250802","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2020.08.005","article-title":"The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas","volume":"105","author":"Prabhakaran","year":"2020","journal-title":"Hum Pathol"},{"key":"R36-20250802","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/PAS.0b013e318033e7a8","article-title":"h-caldesmon, calretinin, estrogen receptor, and ber-ep4: a useful combination of immunohistochemical markers for differentiationg epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary","volume":"31","author":"Comin","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R37-20250802","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/his.13321","article-title":"Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumors","volume":"71","author":"Yoshimura","year":"2017","journal-title":"Histopathology"},{"key":"R38-20250802","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1309\/2H0NVRERPP2LJDUA","article-title":"Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis","volume":"123","author":"Baker","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"R39-20250802","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2012","journal-title":"Nat Genet"},{"key":"R40-20250802","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2015","journal-title":"Nat Genet"},{"key":"R41-20250802","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R42-20250802","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5858\/arpa.2017-0092-OA","article-title":"Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 224 cases","volume":"142","author":"Tandon","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R43-20250802","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/PAS.0000000000000616","article-title":"BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R44-20250802","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.pathol.2016.03.005","article-title":"Loss of expression of BAP1 is very rare in non-small cell lung carcinoma","volume":"48","author":"Andrici","year":"2016","journal-title":"Pathology"},{"key":"R45-20250802","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/modpathol.2016.230","article-title":"Claudin-4 expression distinguishes SWI\/SNF complex-deficient undifferentiated carcinomas from sarcomas","volume":"30","author":"Schaefer","year":"2017","journal-title":"Mod Pathol"},{"key":"R46-20250802","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1066896913491320","article-title":"Claudin-4 as a marker for distinguishing malignant mesothelioma from lung carcinoma and serous adenocarcinoma","volume":"21","author":"Ohta","year":"2013","journal-title":"Int J Surg Pathol"},{"key":"R47-20250802","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2012.200","article-title":"Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas","volume":"26","author":"Ordonez","year":"2013","journal-title":"Mod Pathol"},{"key":"R48-20250802","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res"},{"key":"R49-20250802","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/modpathol.2008.45","article-title":"Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas","volume":"21","author":"Chiosea","year":"2008","journal-title":"Mod Pathol"},{"key":"R50-20250802","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.1111\/j.1365-2559.2012.04196.x","article-title":"The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas","volume":"60","author":"Zimling","year":"2012","journal-title":"Histopathology"},{"key":"R51-20250802","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41379-019-0371-0","article-title":"Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma","volume":"33","author":"Brich","year":"2020","journal-title":"Mod Pathol"},{"key":"R52-20250802","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/0008-5472.CAN-08-3913","article-title":"Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas","volume":"69","author":"Kuo","year":"2009","journal-title":"Cancer Res"},{"key":"R53-20250802","doi-asserted-by":"crossref","first-page":"37663","DOI":"10.18632\/oncotarget.5438","article-title":"Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes","volume":"6","author":"Hunter","year":"2015","journal-title":"Oncotarget"},{"key":"R54-20250802","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/s41379-020-0588-y","article-title":"Molecular characterization of diffuse malignant peritoneal mesothelioma","volume":"33","author":"Hung","year":"2020","journal-title":"Mod Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000877","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:03:11Z","timestamp":1754161391000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PGP.0000000000000877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000000877","relation":{},"ISSN":["0277-1691"],"issn-type":[{"value":"0277-1691","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}